Cellular and molecular effects of resveratrol in health and disease

Journal of Cellular Biochemistry

Volumn 113, Issue 3, 2012, Pages 752-759

  Yu, Wei ^a   Fu, Yu Cai ^b   Wang, Wei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Aging; Cellular Effect; P53; Resveretrol; Signal Transduction Pathway; Sirt1

Indexed keywords

ENDOTHELIN 1; RESVERATROL; SIRTUIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOLOGICAL ACTIVITY; BLADDER CANCER; BREAST CANCER; CHEMICAL STRUCTURE; COLON CANCER; DEGENERATIVE DISEASE; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; GLIOMA CELL; HEART PROTECTION; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; MEDULLOBLASTOMA; MELANOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; NEURODEGENERATIVE DISEASES; PLATELET AGGREGATION INHIBITORS; STILBENES;

VITACEAE;

EID: 84863267798     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23431     Document Type: Review

References (99)

1. Anekonda TS. 2006. Resveratrol-a boon for treating Alzheimer's disease? Brain Res Rev 52: 316-326. (Pubitemid 44291807)
2. Arend WP, Dayer JM. 1995. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38: 151-160.
3. Bai Y, Mao QQ, Qin J, et al. 2010. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 101: 488-493.
4. Banerjee Mustafi S, Chakraborty PK, Raha S. 2010. Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PLoS One 5: e8719.
5. Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 5: 493-506. (Pubitemid 44136961)
6. Bhavnani BR, Cecutti A, Gerulath A, et al. 2001. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause 8: 408-419. (Pubitemid 33111576)
7. Birrell MA, McCluskie K, Wong S, et al. 2005. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J 19: 840-851.
8. Brooks CL, Gu W. 2009. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 9: 123-128.
9. Butler DM, Maini RN, Feldmann M, et al. 1995. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 6: 225-230. (Pubitemid 26018294)
10. Cavallaro A, Ainis T, Bottari C, et al. 2003. Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol Res 52: 555-562. (Pubitemid 37345641)
11. Chao HH, Juan SH, Liu JC, et al. 2005. Resveratrol inhibits angiotensin II-induced endothelin-1 gene expression and subsequent proliferation in rat aortic smooth muscle cells. Eur J Pharmacol 515: 1-9.
12. Chen CJ, Yu W, Wang W. 2010. Red wine may be used in the therapy of myocarditis. J Cell Biochem 111: 808-810.
13. Chen CJ, Yu W, Fu YC, et al. 2009. Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun 378: 389-393.
14. Chen ZH, Hurh YJ, Na HK, et al. 2004. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 25: 2005-2013.
15. Crescente M, Jessen G, Momi S, et al. 2009. Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies. Thromb Haemost 102: 336-346.
16. Csaki C, Mobasheri A, Shakibaei M. 2009. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: Inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 11: R165.
17. Davignon J, Ganz P. 2004. Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-III32. (Pubitemid 38786440)
18. de la Lastra CA, Villegas I. 2005. Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Mol Nutr Food Res 49: 405-430. (Pubitemid 40780389)
19. Dichtl W, Nilsson L, Goncalves I, et al. 1999. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 84: 1085-1094. (Pubitemid 29227688)
20. Donnelly LE, Newton R, Kennedy GE, et al. 2004. Anti-inflammatory effects of resveratrol in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 287: L774-L783. (Pubitemid 39249390)
21. Dorai T, Aggarwal BB. 2004. Role of chemopreventive agents in cancer therapy. Cancer Lett 215: 129-140. (Pubitemid 39370030)
22. El-Mowafy AM, White RE. 1999. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: Reversal of endothelin-1 stimulatory effects. FEBS Lett 451: 63-67. (Pubitemid 29236173)
23. Endres M, Laufs U, Huang Z, et al. 1998. Stroke protection by 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885. (Pubitemid 28350583)
24. Fan E, Zhang L, Jiang S, et al. 2008. Beneficial effects of resveratrol on atherosclerosis. J Med Food 11: 610-614.
25. Fauconneau B, Waffo-Teguo P, Huguet F, et al. 1997. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from vitis vinifera cell cultures using in vitro tests. Life Sci 61: 2103-2110. (Pubitemid 27478837)
26. Feng YH, Zou JP, Li XY. 2002. Effects of resveratrol and ethanol on production of pro-inflammatory factors from endotoxin-activated murine macrophages. Acta Pharmacol 23: 1002-1006.
27. Frémont L. 2000. Biological effects of resveratrol. Life Sci 66: 663-673.
28. Fulgenzi A, Bertelli AA, Magni E, et al. 2001. In vivo inhibition of TNFalphainduced vascular permeability by resveratrol. Transplant Proc 33: 2341-2343. (Pubitemid 33762735)
29. Gatouillat G, Balasse E, Joseph-Pietras D, et al. 2010. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J Cell Biochem 110: 893-902.
30. Hao HD, He LR. 2004. Mechanisms of cardiovascular protection by resveratrol. J Med Food 7: 290-298. (Pubitemid 39299486)
31. Hsieh TC, Juan G, Darzynkiewicz Z, et al. 1999. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21WAF1/CIP1, and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res 59: 2596-2601. (Pubitemid 29269105)
32. Jackson JR, Ryan MJ, Alway SE. 2011. Long-term supplementation with resveratrol alleviates oxidative stress but does not attenuate sarcopenia in aged mice. J Gerontol A Biol Sci Med Sci 66: 751-764.
33. Jang JH, Surh YJ. 2001. Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat Res 496: 181-190.
34. Jang M, Cai L, Udeani GO, et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220. (Pubitemid 127696281)
35. Jiang H, Shang X, Wu H, et al. 2010. Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells. Neurochem Res 35: 152-161.
36. Jin F, Wu Q, Lu YF, et al. 2008. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol 600: 78-82.
37. Jing YH, Chen KH, Yang SH, et al. 2010. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: Role of AGE-RAGE signalling. Diabetes Metab Res Rev 26: 212-222.
38. Kai L, Samuel SK, Levenson AS. 2010. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer 126: 1538-1548.
39. Kang L, Heng W, Yuan A, et al. 2010. Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: Relative to inhibition of inflammatory responses. Biochimie 92: 789-796.
40. Kang OH, Jang HJ, Chae HS, et al. 2009. Anti-inflammatory mechanisms of resveratrol in activated HMC-1cells: Pivotal roles of NF-kappaB and MAPK. Pharmacol Res 59: 330-337.
41. Karin M, Delhase M. 1998. JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action? Proc Natl Acad Sci USA 95: 9067-9069. (Pubitemid 28506184)
42. Karin M, Liu Z, Zandi E. 1997. AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246. (Pubitemid 27135992)
43. Karuppagounder SS, Pinto JT, Xu H, et al. 2009. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54: 111-118.
44. Khan MM, Ahmad A, Ishrat T, et al. 2010. Resveratrol attenuates 6-hydroxydopamine- induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res 1328: 139-151.
45. Kim D, Nguyen MD, Dobbin MM, et al. 2007. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26: 3169-3179. (Pubitemid 47057498)
46. Kim YH, Kim YS, Kang SS, et al. 2010. Resveratrol inhibits neuronal apoptosis and elevated Ca2+/calmodulin-dependent protein kinase II activity in diabetic mouse retina. Diabetes 59: 1825-1835.
47. Kinlay S, Libby P, Ganz P. 2001. Endothelial function and coronary artery disease. Curr Opin Lipidol 12: 383-389. (Pubitemid 32675498)
48. Kong G, Kim EK, Kim WS, et al. 2002. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 17: 914-921.
49. Kundu JK, Surh YJ. 2004. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat Res 555: 65-80. (Pubitemid 39345398)
50. Kweon SH, Song JH, Kim TS. 2010. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 395: 104-110.
51. Lee MK, Kang SJ, Poncz M, et al. 2007. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med 39: 376-384. (Pubitemid 47037629)
52. Leiro J, Alvarez E, Arranz JA, et al. 2004. Effects of cis-resveratrol on inflammatory murine macrophages: Antioxidant activity and down- regulation of inflammatory genes. J Leukoc Biol 75: 1156-1165. (Pubitemid 38720660)
53. Liu BQ, Gao YY, Niu XF, et al. 2010. Implication of unfolded protein response in resveratrol-induced inhibition of K562 cell proliferation. Biochem Biophys Res Commun 391: 778-782.
54. Liu JC, Chen JJ, Chan P, et al. 2003. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 42: 1198-1205. (Pubitemid 37549077)
55. Lorenz P, Roychowdhury S, Engelmann M, et al. 2003. Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: Effect on nitrosative and oxidative stress derived from microglial cells. Nitric Oxide 9: 64-76. (Pubitemid 37386375)
56. Manna SK, Mukhopadhyay A, Aggarwal BB. 2000. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164: 6509-6519. (Pubitemid 30408836)
57. Marambaud P, Zhao H, Davies P. 2005. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 280: 37377-37382. (Pubitemid 41642343)
58. Markus MA, Morris BJ. 2008. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 3: 331-339. (Pubitemid 352037871)
59. Marques FZ, Markus MA, Morris BJ. 2009. Resveratrol: Cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 41: 2125-2128.
60. Martinez J, Moreno J. 2000. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 59: 865-870. (Pubitemid 30081710)
61. Mietus-Snyder M, Gowri MS, Pitas RE. 2000. Class A scavenger receptor upregulation in smooth muscle cells by oxidized low density lipoprotein. Enhancement by calcium flux and concurrent cyclooxygenase-2 up-regulation. J Biol Chem 275: 17661-17670. (Pubitemid 30430814)
62. Miura T, Muraoka S, Ikeda N, et al. 2000. Antioxidative and prooxidative action of stilbene derivatives. Pharmacol Toxicol 86: 203-208. (Pubitemid 30333646)
63. Pace-Asciak CR, Rounova O, Hahn SE, et al. 1996. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 246: 163-182. (Pubitemid 26094547)
64. Palsamy P, Subramanian S. 2009. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem Biol Interact 179: 356-362.
65. Palsamy P, Subramanian S. 2010. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol 224: 423-432.
66. Papoutsis AJ, Lamore SD, Wondrak GT, et al. 2010. Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J Nutr 140: 1607-1614.
67. Penumathsa SV, Thirunavukkarasu M, Zhan L, et al. 2008. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med 12: 2350-2361.
68. Pervaiz S. 2003. Resveratrol: From grapevines to mammalian biology. FASEB J 17: 1975-1985. (Pubitemid 37392442)
69. Puissant A, Robert G, Fenouille N, et al. 2010. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK- mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 70: 1042-1052.
70. Renaud S, de Lorgeril M. 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
71. Rubbo H, Trostchansky A, Botti H, et al. 2002. Interactions of nitric oxide and peroxynitrite with low-density lipoprotein. Biol Chem 383: 547-552. (Pubitemid 34506290)
72. Ryan MJ, Jackson JR, Hao Y, Williamson CL, Dabkowski ER, Hollander JM, Alway SE. 2010. Suppression of oxidative stress by resveratrol after isometric contractions in gastrocnemius muscles of aged mice. J Gerontol A Biol Sci Med Sci 65: 815-831.
73. Saiko P, Szakmary A, Jaeger W, et al. 2008. Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 658: 68-94. (Pubitemid 351172881)
74. Schmatz R, Mazzanti CM, Spanevello R, et al. 2009. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin- induced diabetic rats. Eur J Pharmacol 610: 42-48.
75. Shakibaei M, Harikumar KB, Aggarwal BB. 2009. Resveratrol addiction: To die or not to die. Mol Nutr Food Res 53: 115-128.
76. Shu XH, Li H, Sun Z, et al. 2010. Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem Pharmacol 79: 1516-1525.
77. Stojanovic S, Sprinz H, Brede O. 2001. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 391: 79-89. (Pubitemid 32612575)
78. Subbaramaiah K, Chung WJ, Michaluart P, et al. 1998. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273: 21875-21882. (Pubitemid 28405365)
79. Sulaiman M, Matta MJ, Sunderesan NR, et al. 2010. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 298: H833-H843.
80. Sun M, Qian F, Shen W, Tian C, Hao J, Sun L, Liu J. 2011. Mitochondrial nutrients stimulate performance and mitochondrial biogenesis in exhaustively exercised rats. Scand J Med Sci Sports DOI: 10.1111/j.1600-0838.2011. 01314.x.
81. Sun X, Zhang Y, Wang J, et al. 2010. Beta-arrestin 2 modulates resveratrolinduced apoptosis and regulation of Akt/GSK3ß pathways. Biochim Biophys Acta 1800: 912-918.
82. Suzuki K, Koike T. 2007. Resveratrol abolishes resistance to axonal degeneration in slow Wallerian degeneration (WldS) mice: Activation of SIRT2, an NAD-dependent tubulin deacetylase. Biochem Biophys Res Commun 359: 665-671. (Pubitemid 46899003)
83. Tikoo K, Singh K, Kabra D, et al. 2008. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 42: 397-404.
84. Tili E, Michaille JJ, Adair B, et al. 2010. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 31: 1561-1566.
85. Tsai SH, Lin-Shiau SY, Lin JK. 1999. Suppression of nitric oxide synthase and the down-regulation of the activation of NF-κB in macrophages by resveratrol. Br J Pharmacol 126: 673-680.
86. Ungvari Z, Bagi Z, Feher A, et al. 2010. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 299: H18-H24.
87. Ungvari Z, Labinskyy N, Mukhopadhyay P, et al. 2009. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 297: H1876-H1881.
88. Vanamala J, Reddivari L, Radhakrishnan S, et al. 2010. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 10: 238.
89. Wang J, Ho L, Zhao Z, et al. 2006. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 20: 2313-2320. (Pubitemid 44953861)
90. Wang S, Wang X, Yan J, et al. 2007. Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: Correlated with NO-cGMP signaling pathway. Eur J Pharmacol 567: 26-35. (Pubitemid 46795491)
91. Wang TT, Schoene NW, Kim YS, et al. 2010. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen- responsive LNCaP cancer cells. Mol Nutr Food Res 54: 335-344.
92. Weng CJ, Wu CF, Huang HW, et al. 2010. Evaluation of anti-invasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. J Agric Food Chem 58: 2886-2894.
93. Wu CC, Wu CI, Wang WY, et al. 2007. Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins. Planta Med 73: 439-443.
94. Yang YM, Chen JZ, Wang XX, et al. 2008a. Resveratrol attenuates thromboxane A2 receptor agonist-induced platelet activation by reducing phospholipase C activity. Eur J Pharmacol 583: 148-155.
95. Yang YM, Wang XX, Chen JZ, et al. 2008b. Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity. Am J Chin Med 36: 603-613.
96. 2-induced apoptosis and expression of SIRTs in H9c2cells.J Cell Biochem 107: 741-747.
97. Zhang H, Zhang J, Ungvari Z, et al. 2009. Resveratrol improves endothelial function: Role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol 29: 1164-1171.
98. Zhong M, Cheng GF, Wang WJ, et al. 1999. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 6: 79-84. (Pubitemid 129634463)
99. Zou JG, Wang ZR, Huang YZ, et al. 2003. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int J Mol Med 11: 317-320.